Abstract
370 Nurse Prescribing 2015 Vol 13 No 8 © 2 01 5 M A H ea lth ca re L td Participants were randomly assigned to receive either panobinostat together with bortezomib and dexamethasone, or this combination without panobinostat. In patients taking the panobinostat combination, the disease progressed more slowly by a median of 7.8 months, which was considered significant. However, there were several sideeffects associated with the drug, some of which can be serious. The CHMP considered that the positive benefits of the drug outweigh the risks of these sideeffects only in patients with relapsed and/ or refractory myeloma who have had at least two previous treatments including bortezomib and an immunomodulatory First HDAC inhibitor to treat multiple myeloma set for approval in Europe
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
